Omalizumab shows superior efficacy to dupilumab in reducing symptoms in patients with chronic spontaneous urticaria.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results